SCHEMBL5149059

SCHEMBL5149059

CC(C)n1nc(-c2nc(OCC(F)(F)F)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 6/20 0.35
FGFR3 P22607 6/20 0.35
FGFR1 P11362 4/20 0.35
SCN9A Q15858 2/20 0.34
PIK3CA P42336 1/20 0.33
MAP3K12 Q12852 3/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
ABL1 P00519 1/20 0.33
SRC P12931 1/20 0.33
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149200 0.86 SRC (0.43) FGFR2FGFR3FGFR1PIK3CAABL1
SCHEMBL5149212 0.85 SRC (0.40) FGFR2FGFR3FGFR1HRH3ABL1
SCHEMBL5152824 0.85 MPO (0.38) FGFR2FGFR3FGFR1PIK3CAMAP3K12
SCHEMBL5147947 0.85 HRH3 (0.34) FGFR2FGFR3FGFR1HRH3ABL1
SCHEMBL5150959 0.84 FGFR1 (0.39) FGFR2FGFR3FGFR1PIK3CAABL1
SCHEMBL5148967 0.84 HRH3 (0.36) FGFR2FGFR3FGFR1PIK3CAHRH3
SCHEMBL5148946 0.84 SMN1; SMN2 (0.37) FGFR2FGFR3FGFR1PIK3CAHRH3
SCHEMBL5152823 0.83 ADORA2A (0.41) FGFR2FGFR3FGFR1HRH3ADORA2A
SCHEMBL5149050 0.83 FGFR1 (0.36) FGFR2FGFR3FGFR1PIK3CAHRH3
SCHEMBL5149189 0.83 SYK (0.42) ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 FGFR2 3554/4885FGFR3 3438/4885FGFR1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.